


8. The Vaccine Vial Monitor : Vaccine Vial Monitors (VVM3) dot is a part of the label on **Typhar TCV**[®] vials supplied through Bharat Biotech, VVM30 are supplied by TEMPTIME Corporation, USA. This is a time-temperature sensitive dot that provides an indication of the cumulative heat to which the vial has been exposed. It warns the end user when exposure to heat is likely to have degraded the vaccine beyond an acceptable level.



The interpretation of the VVM30 is simple: Focus on the central square; its colour will change progressively. As long as the colour of this square is lighter than the colour of the ring, the vaccine can be used. As soon as the colour of the central square is the same colour as the ring or a darker colour than the ring, the vial should be discarded.

9.0 Stability under Extended Controlled Temperature Conditions (WHO-ECTC guidelines)

This vaccine has been proven to remain stable for use beyond the traditional +2°C to +8°C cold chain under monitored conditions in keeping with the CTC, as defined by the World Health Organization. If an immunization programme decides it is advantageous to apply a CTC strategy to delivery of this vaccine, it may do so according to one of the following two options: (a) removal from the traditional +2°C to +8°C cold chain for up to THREE consecutive days just prior to administration, when stored or transported at temperatures not exceeding 55°C; or (b) removal from the traditional +2°C to +8°C cold chain for up to SEVEN consecutive days just prior to administration, when stored or transported at temperatures not exceeding 40°C. Once unopened vaccine vials are brought into either of these CTC scenarios, they must be used within the selected and tracked CTC time frame or appropriately discarded. All vials opened during an immunization session must be discarded after 8 hours or at the end of the session, whichever occurs first. The WHO recommends the use of an additional peak temperature threshold indicator to monitor that vaccines are not exposed to temperatures above the permitted threshold. Additional guidance on implementing a CTC delivery strategy is available from the World Health Organization.

References:

- Mohan VK, Varanasi V, Singh A, Levine MM, Venkatesan R, Ella KM. "Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typhar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study". *Clin Infect Dis*. 2015 Aug 1;61(3):393-402. doi: 10.1093/cid/civ295, Epub 2015 Apr 13.
- Voysey M, Pollard AJ. Seroreactivity of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typhar TCV)[®]. *Clin Infect Dis*. 2018 Jun 18;67(11):18-24. doi: 10.1093/cid/cix1145.
- Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, Harris V, Harris V, Gardner J, Nebykova A, Kemridge SA, Hill J, Thomaidis-Brears H, Blohmke CJ, Yu LM, Angus B, Pollard AJ. "Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial". *Lancet*. 2017 Dec 2;390(10111):2472-2480. doi: 10.1016/S0140-6736(17)32149-8, Epub 2017 Sep 28.
- Shakya M, Collin-Jones R, Theiss-Nyland K, Voysey M, Pant D, Smith N, Liu X, Tonks S, Mazur O, Farooq UG, Clarke J, Hill J, Adhikari A, Dongol S, Karkey A, Bajracharya B, Kelly S, Gurung M, Baker S, Neuzil KM, Shrestha S, Basnyat B, Pollard AJ. TYVAC Nepal Study Team. "Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal". *N Engl J Med*. 2019 Dec 5;381(23):2209-2218. doi: 10.1056/NEJMoa1905047.
- Qamar FN, Yousafzai MT, Khaliq A, Karim S, Memon H, Junejo A, Baig I, Rahman N, Bhurgry S, Afroz H, Sami U. Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan, Vaccine, 2020 Apr 23;38(19):3518-3523. doi: 10.1016/j.vaccine.2020.03.028. Epub 2020 Mar 20. PMID: 32201138; PMCID: PMC7166079.
- "Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India". Available at: <https://clinicaltrials.gov/ct2/show/NCT03554213>.
- Meiring J-E, Laurens MB, Patel P, Patel P, Misiri S, Simiyu K, Mwakiseghe F, Tracy JK, Masesa C, Liang Y, Henrion M, Rotroen E, Gmeiner M, Heyderman R, Kotloff K, Gordon MA, Neuzil KM. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi. *Clin Infect Dis*. 2019 Mar 7;68(Suppl 2):S50-S58. doi: 10.1093/cid/ciy1103. PMID: 30845320; PMCID: PMC6405266.
- Sirima SB, Quedrogo A, Barry N, Siribie M, Tiro AB, Nèbié J, Konaté AT, Berges GD, Diarra A, Quedrogo M, Soulama I, Hema A, Diatta S, Liang Y, Rotroen ET, Tracy JK, Jamka LP, Neuzil KM, Laurens MB. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso. *Int J Infect Dis*. 2021 Jan;102:517-523. doi: 10.1016/j.ijid.2020.10.103. Epub 2020 Nov 8. PMID: 33176205; PMCID: PMC7762715.
- Theiss-Nyland K, Qadr F, Collin-Jones R, Zaman K, Khanam F, Liu X, Voysey M, Khan A, Hasan N, Ashier F, Farooq UG, Pollard AJ, Clemens JD. Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIb Trial. *Clin Infect Dis*. 2019 Mar 7;68(Suppl 2):S74-S82. doi: 10.1093/cid/ciy1107. PMID: 30845333; PMCID: PMC6405281.
- "SAGE on Typhoid Vaccine Policy Recommendations" available at: https://www.who.int/immunization/sage/meetings/2017/october/1_Typhoid_SAGE_background_paper_Final_v3b.pdf?ua=1
- "Safety of typhoid conjugate vaccine" available at: https://www.who.int/vaccine_safety/committee/topics/typhoid/Dec_2018/en/

Last revision date: August 2021

Manufactured & Marketed by:



Bharat Biotech International Limited,
 Sy, No. 230, 231 & 235, Genome Valley, Turkapally, Shamirpet Mandal, Medchal - Malkajgiri District - 500 076, Telangana State, India.
 For complaints and suggestions about the product, and any adverse event, Please email feedback@bharatbiotech.com or call on Toll free number 1800 102 2245 www.bharatbiotech.com

76PD.05
140002141

For use of Registered Medical Practitioner or a Hospital.

टाइफाइड विआई कांजूट वैसीन आईपी
Typhoid Vi Conjugate Vaccine IP
 टाइपवार टिसिवि

1. NAME AND DESCRIPTION OF THE MEDICINAL PRODUCT

Typhar TCV[®] is a clear to slightly turbid liquid containing purified Vi capsular polysaccharide of *Salmonella Typhi* Ty2 conjugated to a non-toxic carrier protein, Tetanus Toxoid, Vi Capsular Polysaccharide of *Salmonella Typhi* alone elicits B cell response, but the conjugation of bacterial polysaccharide to a protein carrier provides foreign peptide antigens that are presented to the immune system eliciting antigen specific CD4⁺ T_H1 cells in what is referred to as T cell dependent antibody responses. A hallmark of T cell dependent responses, which are also elicited by toxoid is to induce both higher-affinity antibodies and long-term immune memory.

Prevention becomes effective in 2-3 weeks after immunization, **Typhar TCV**[®] protects against typhoid fever caused by *Salmonella Typhi*. Protection is not conferred against *Salmonella Paratyphi* and other non-typhoidal *Salmonellae* causing typhoid infection.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

a) Composition for single dose presentation in vial

Each dose of 0.5 mL contains	
Purified Vi Capsular Polysaccharide of <i>Salmonella typhi</i> Ty2 conjugated to Tetanus Toxoid	25 µg
Sodium Chloride IP	4.5 mg
Water for Injections IP	q.s. to 0.5 mL

b) Composition for multi-dose presentation in vial

Each dose of 0.5 mL contains:	
Purified Vi Capsular Polysaccharide of <i>Salmonella typhi</i> Ty2 conjugated to Tetanus Toxoid	25 µg
Sodium Chloride IP	4.5 mg
2-Phenoxyethanol IP	5.0 mg
Water for Injections IP	q.s. to 0.5 mL

3. PHARMACEUTICAL FORM: Sterile Solution for Injection.

4. CLINICAL PARTICULARS

4.1 Therapeutic Indications

Typhar TCV[®] is indicated in infants, children and adults (≥6 months age group) for active immunization against *Salmonella Typhi* infection.

4.2 Posology, Schedule and Method of Administration

Inject 0.5 mL intramuscularly.
 • Single dose: 1 dose (0.5mL) in ≥6 months to ≤65 years age group

Typhar TCV[®] should be given intramuscularly in the vastus lateralis (anterolateral aspect of thigh) in infants <12 months of age or in the deltoid (upper arm) muscle in children ≥12 months of age. **Typhar TCV**[®] should not be injected into the gluteal area or areas where there may be a nerve trunk.

4.3 Contraindications

- Hypersensitivity to any constituent of the vaccine.
- 4.4 Special Warning / Precautions**
 - Do not administer intravenously, intradermally, or subcutaneously.
 - Like all other vaccines, supervision and appropriate medical treatment should always be available to treat any anaphylactic reactions following immunization.
 - During fever or severe infection, Epinephrine injection (1:1000) must be immediately available in case of an acute anaphylactic reaction or any allergic reaction occurs due to any component of the vaccine.

4.5 Interaction with other medicinal products/ other forms of interaction

All commonly used vaccines (except pneumococcal vaccines) can safely and effectively administered simultaneously (on the same day) at separate sites without impairing antibody responses or increasing rates of adverse reactions.

Typhar TCV[®] should NOT be mixed with any other vaccine or medicinal product, because the interactions with other vaccines or medicinal products have not been established.

4.6 Pregnancy and Lactation

Safety has not been established in pregnant women and in nursing mothers.

4.7 Effect on ability to drive and use machines

No studies on the effect of **Typhar TCV**[®] on the ability to drive and use machines have been performed.

4.8 Undesirable effects

Clinical Trial Experience
 The safety and immunogenicity of **Typhar TCV**[®] vaccine was established in phase 2 and 3 clinical trials. In a phase 2 clinical trial conducted in India among 100 children aged 2-17 years, no significant adverse events were demonstrated to be associated with the vaccine. Commonly reported adverse events included pain and swelling at injection site, fever and headache.

In the larger phase 3 clinical trial, a total of 981 healthy subjects were enrolled into the study at 8 clinical sites into 2 study cohorts. A single arm, open label cohort enrolled 327 subjects between the age of ≥6 months to 2 years to receive a single dose of **Typhar TCV**[®]. A second randomized controlled arm recruited 654 subjects between the age >2 years to 45 years, allocated equally to receive a single dose of either **Typhar TCV**[®] or a comparator Vi Polysaccharide vaccine.

The most common general and local adverse events were fever (4-10%) and pain (3-4%) and swelling (1-2%) at injection site, post vaccination. All these events were resolved within 48 hours with symptomatic treatment. Uncommon adverse events observed were tenderness, and erythema at injection site, arthralgia, malaise and myalgia. No differences were observed in the adverse events reported between Typhoid Polysaccharide vaccine (Typhar) and **Typhar TCV**[®]. The adverse events reported were similar in nature as reported with other commercial Vi vaccines. No vaccine-related serious adverse events (SAEs) were reported in the clinical trial.

Post-Marketing Experience

Post-Marketing Surveillance – Active and Passive surveillance was conducted in approximately 10000 vaccine recipients of **Typhar TCV**[®].

Active surveillance was performed by physicians provided with PMS forms to report any observed adverse events. Passive surveillance was performed by voluntary reporting of adverse events by pediatricians/physicians across India. The adverse reactions observed in the PMS study were ranked under headings of frequency of occurrence using the following convention:

Very common	: ≥10%
Common	: ≥ 1% and < 10%
Uncommon	: ≥ 0.1% and < 1%
Rare	: ≥ 0.01% and < 0.1%
Very rare	: < 0.01%

Fever, pain and swelling at injection site, pruritus/itching were common, whereas cough and cold are uncommon. Persistent crying, rash, Generalized Tonic Clonic Seizures (GTCS), chills and rigors were rare. The above events were reported from the post marketing surveillance study and it is not always possible to establish a causal relationship of these events to the product.

4.9 Overdose

No case of overdose has been reported

4.10 Immune response

4.10.1 Phase 3 clinical study¹

The phase 3 clinical trial that enrolled 981 healthy subjects into the trial across two age cohorts had 654 subjects aged >2 to <45 years (RCT) received a single dose of **Typhar TCV**[®] or Vi Polysaccharide vaccine and other 327 subjects aged <6 months to <2 years (OLT) received a single dose of **Typhar TCV**[®] vaccine only.

After a single dose of the vaccine, seroconversion (≥4-fold increase of anti-ViG antibodies) at 6 weeks post-vaccination in subjects aged 6 months to <2years, >2 to <5 years, >5 to <15 years and >15 to <45 years was 98.1%, 99.3%, 99.3% and 91.9%, respectively.

Subjects were followed up for long term immunogenicity for a period of 3 and 5 years post-vaccination. Seroconversion rates (% with ≥4-fold increase in anti-Vi titer over baseline at day 0) of **Typhar TCV**[®] subjects at 3 and 5 years after vaccination in the RCT group (>2 to <45 years) remained to be high at 76.8% and 70.4% respectively. Similarly in the OLT (>6months to <2 years), ≥ 4-fold seroconversion rates of **Typhar TCV**[®] subjects at 3 and 5 years after vaccination are 78.1% and 76.8% respectively.

Seroefficacy study²:

University of Oxford, U.K. estimated the seroefficacy of **Typhar TCV**[®] vaccine as 85% and showed that **Typhar TCV**[®] substantially reduces the number of serologically defined clinical or subclinical infections in infants, children, and adults compared to the Vi-PS vaccine.

4.10.2 Phase 4 Clinical Studies

TCV Measles non-interference study: In a Phase 4 TCV Measles non-interference study, a total of 500 healthy infants of age group of 8 to 10 months were enrolled in this study.

Group 1: **Typhar TCV**[®] & Measles co-administration at 9 months.

Group 2: Measles at 9 months and **Typhar TCV**[®] at 10 months.

Group 3: **Typhar TCV**[®] at 8 months and Measles at 9 months.

Group 4: Only Measles at 9 months.

MMR vaccine was administered to all the 4 groups at 15 months of their age. Antibody responses to **Typhar TCV**[®] and Measles in terms of GMT and 4-fold seroconversion on day 28 post vaccination were higher in Group 1 as compared to Group 2, 3 and 4. The above results indicate that concomitant administration of **Typhar TCV**[®] and Measles containing vaccine/MMR does not influence the antibody titers either ways and that the titers are higher in the groups where concomitant administration of TCV and Measles was done. The safety profiles for each vaccination regimen were comparable and clinically acceptable. Based on the immunogenicity results, Concomitant administration of **Typhar TCV**[®] and Measles at 9 months of age revealed that the immune responses with respect to each antigen (i.e., Anti Vi IgG and Anti-measles IgG titers in terms of GMT and 4 fold seroconversion) was non-inferior to the response seen when the vaccines are administered alone. The immunogenicity data support concomitant administration of Measles containing vaccine/MMR with **Typhar TCV**[®].

Typhar TCV[®] meningococcal type-A non-interference study: Group 1: **Typhar TCV**[®] & Measles co-administration at 9 months. In Burkina Faso, a double-blind, randomized controlled trial was done to assess the safety and immunogenicity in children aged 15-23 months. In this study meningococcal type-A and measles-rubella vaccine is co-administered with typhoid conjugate. A total of 150 children were recruited and vaccinated and there were 176 participants were divided into three groups.

Group 1- **Typhar TCV**[®], IPV and MR are co-administered.

Group 2: **Typhar TCV**[®], MR and MCV-A are co-administered.

Group 3: IPV, MR and MCV-A are Co-administered.

The results show that TCV can be safely co-administered at 15 months with MCV-A without interference, This novel study on the co-administration of TCV with MCV-A provides data to support large-scale uptake in sub-Saharan Africa.

Typhar TCV[®] comparator study:

In the comparator phase 4 study (340 subjects), non-inferiority in the immune response of **Typhar TCV**[®] as compared to Typhim Vi[®] has been examined. While safety profile of **Typhar TCV**[®] is comparable to that of a WHO-prequalified typhoid vaccine – Typhim Vi[®], its immune response, as measured by anti-Vi IgG titers – 28 days post vaccination, is non-inferior to Typhim Vi[®] vaccine.

Typhar TCV[®] safety & immunogenicity in older adults:

The phase 4 clinical trial that enrolled 300 healthy subjects into the trial across two age cohorts had 100 subjects aged >18 to <45 years (cohort 1) and other 200 subjects aged >45 years to <65 years (cohort 2) received a single dose of **Typhar TCV**[®] vaccine. After a single dose of the vaccine, Geometric mean titers of anti-Vi IgG antibody at pre- and post-vaccination in cohort 1 subjects were 12 EU/mL, 1468.81 EU/mL and in cohort 2 subjects were 13.01 EU/mL, 1568.22 EU/mL respectively. The results indicating that the **Typhar TCV**[®] is safe and equally immunogenic in older adults.

4.10.3 A Phase 2b Human Challenge Study³

A Phase 2b Human Challenge study was conducted at Oxford University, UK using controlled human infection model of *Salmonella Typhi*. A total of 112 participants were randomly assigned (1:1:1) to receive a single parenteral dose of **Typhar TCV**[®], Vi-PS-Typhim Vi, or control, meningococcal ACWY-CRM conjugate vaccine. About 1-month post-vaccination, participants were challenged orally with 1-5 × 10⁹ colony forming units (CFUs) of S Typhi Qualles strain. The participants were followed up for a 2-week period post challenge for diagnosis of Typhoid fever. When an approximate field definition of typhoid fever was applied, such

as fever ≥38.0°C followed by bacteraemia, the estimated vaccine efficacy of **Typhar TCV**[®] was 87.1% as compared to 52.3% in Typhim Vi[®] group. Four-fold Seroconversion rate of **Typhar TCV**[®] was 100% compared to 88.6% for Typhim Vi[®].

4.10.4 Efficacy and effectiveness studies across the globe

Efficacy and effectiveness studies are conducting in several countries, such as Nepal, Bangladesh, Burkina Faso, Malawi, India and Pakistan.

Nepal⁴:

A randomised controlled trial was conducted in Nepal to assess safety and efficacy of TCV in children from 9 months to 15 years of age, in which participants were randomised 1:1 to TCV or a capsular group A meningococcal vaccine. Approximately 20,000 children living in the Lalitpur district within Kathmandu valley, were enrolled in the study, and followed to measure both safety and efficacy data, which will include adverse events, hospitalisations, antibiotic use, and fever frequency. **Typhar TCV**[®] vaccine is found to be safe and well tolerated with 81.6% vaccine efficacy.

Pakistan⁵:

Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (**Typhar-TCV**)[®] was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Fever was followed by local reactivity 144/207,000 (1.89%). No serious AEFI was observed. Administration of a single dose of **Typhar-TCV**[®] among children aged 6 months to 10 years old during an outbreak setting of Hyderabad Pakistan was safe. At the same time as the campaign, researchers set up a surveillance system in the same area over an 18-month period to screen a cohort of over 20,000 children, who received the vaccine, to detect cases of typhoid. They found that 9 out of 10 children in the cohort, or 89%, did not contract the disease.

India⁶:

The Navi Mumbai Municipal Corporation (NMMC), India took a landmark decision to be the first in the world to introduce Typhoid Conjugate Vaccine (**Typhar TCV**)[®] into its immunization program, in two phases. This campaign marked the first public-sector introduction of TCV globally and aimed to vaccinate approximately 390,000 children aged 9 months to under 15 years. The events will reported through the routine AEFI surveillance and active phone follow-ups.

Malawi⁷:

The TyVac conducted a phase 3 randomized, blinded, controlled clinical efficacy trial of typhoid Vi-capsular conjugate vaccine in Malawian children ages 9 months to 12 years. Participants were randomized in a 1:1 ratio to receive either typhoid Vi-capsular conjugate vaccine or meningococcal serogroup A conjugate vaccine. The subset of 200 children aged 9-11 months received typhoid Vi-capsular conjugate vaccine co-administered with measles-rubella vaccine at a different anatomic site. It was reported that **Typhar TCV**[®] vaccine is highly immunogenic (~500 fold increase from baseline titer) and non-interferate with the Measles vaccine.

Burkina Faso⁸:

A double-blind, randomized controlled trial was done to assess the safety and immunogenicity in children aged 15-23 months. In this study meningococcal type-A and measles-rubella vaccine is co-administered with typhoid conjugate. The study was conducted in 150 children and the results show that TCV can be safely co-administered at 15 months with MCV-A without interference. This novel study on the co-administration of TCV with MCV-A provides data to support large-scale uptake in sub-Saharan Africa.

Bangladesh⁹:

A observer-blinded, cluster-randomized, controlled trial with 2 years follow-up to assess the protective impact of the Vi-TCV vaccine in children aged 9 months to <16 years. Approximately, 32500 participants were enrolled and in that >4800 participants had AEs assessed at 1 week following vaccination. Mild fever was the most common AE in both vaccine groups.

WHO SAGE Noted¹⁰:

SAGE re-emphasized the importance of programmatic use of typhoid vaccines for controlling endemic disease. Following review of results from different clinical trials of **Typhar TCV**[®] and other similar typhoid conjugate vaccines, SAGE recommended the introduction of typhoid conjugate vaccine for infants and children over 6 months of age as a single dose in typhoid endemic countries. Routine programmatic administration of TCV is likely to be most feasible at existing vaccine visits at 9 months (Co-administration of measles and measles-mumps-rubella vaccines) of age or in the second year of life.

Introduction of Typhoid Conjugate Vaccine should first be prioritized for countries with the highest burden of disease or a high burden of antibiotic resistant *Salmonella Typhi*. Reviewing epidemiological and modeling data, SAGE and GACVS recommended catch-up vaccination when feasible, with priority for catch up in the youngest age groups (up to 15 years of age), noting that the burden of disease and programmatic feasibility are greater in this age range than in adults. Weekly Epidemiological Record, No 48, 1st December 2017 and WHO Weekly Epidemiological Record on 25 January 2019 (Extract from report of GACVS meeting of 5-6 December 2018)¹¹

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties & Pharmacokinetic Properties

Evaluation of pharmacodynamic and pharmacokinetic properties is not required for vaccines.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients

- Sodium chloride
- 2-Phenoxyethanol (Multi dose presentation)

6.2 Incompatibilities

This vaccine must not be mixed with other medicinal products.

6.3 Shelf Life

The expiry date of the vaccine is indicated on the label and carton of the product.

6.4 Special Precautions for Storage

Store at 2°C to +8°C. Do not freeze. Discard if frozen. Shake well before use. Keep out of reach of children. Do not use the vaccine after the expiration date shown on the label. For multi dose vials use different syringe each time to vaccinate. After first opening, the vaccine can be used for up to 28 days provided.

- It is stored between 2°C - 8°C
- It is NOT delivered in a Controlled Temperature Chain (CTC) programme. Should this be the case, the vaccine should be discarded after 6 hours or at the end of the session, whichever occurs first.

Refer Section 9 for Extended Controlled Temperature Conditions.

7. PRESENTATION

Typhar TCV[®] is presented in USP type 1 glass vial,

- Single dose Vial : 0.5 mL
- Multi dose Vial : 2.5 mL

Front

Back